Genome Editing in iPSCs
Quick Facts
| Feature | Information |
|---|---|
| Primary Application | Precise Genetic Modification of iPSCs |
| Common Technologies | CRISPR-Cas9, Base Editing, Prime Editing |
| Major Uses | Disease Modeling, Mutation Correction, Reporter Lines |
| Typical Validation | Sequencing, Karyotyping, Pluripotency Assessment |
| Biosafety Level | BSL-2 |
Overview
Genome editing enables precise modification of induced pluripotent stem cells (iPSCs), allowing researchers to investigate gene function, model human disease, generate isogenic controls, and create reporter cell lines.
When combined with patient-derived iPSCs, genome editing provides powerful human models that preserve the patient's genetic background while introducing or correcting specific genetic variants.
Major applications include:
- Disease modeling
- Mutation correction
- Functional genomics
- Reporter line generation
- Drug discovery
- Cell therapy research
Why Edit iPSCs?
iPSCs combine several important advantages:
- Unlimited self-renewal
- Human genetic background
- Differentiation into virtually any cell type
Genome editing adds:
- Precise genetic manipulation
- Controlled mutation introduction
- Mutation correction
- Targeted reporter insertion
Together these enable highly reproducible human disease models.
Major Genome Editing Technologies
CRISPR-Cas9
The most widely used genome editing system.
Applications include:
- Gene knockout
- Gene knock-in
- Disease mutation engineering
- Reporter line generation
DNA repair occurs primarily through:
- Non-Homologous End Joining (NHEJ) for gene disruption
- Homology-Directed Repair (HDR) for precise sequence insertion or correction
Base Editing
Base editors introduce single-nucleotide changes without creating double-strand DNA breaks.
Common applications include:
- Point mutation correction
- Disease variant generation
- Precision editing with reduced indel formation
Prime Editing
Prime editing combines a Cas9 nickase, reverse transcriptase, and guide RNA to introduce precise sequence changes without donor DNA.
Applications include:
- Point mutations
- Small insertions
- Small deletions
CRISPRi and CRISPRa
Catalytically inactive Cas9 (dCas9) can regulate gene expression without altering DNA sequence.
CRISPRi
- Gene repression
- Functional genomics
- Target validation
CRISPRa
- Gene activation
- Gain-of-function studies
- Gene regulatory analysis
Common Editing Strategies
Gene Knockout
Loss-of-function studies generated through NHEJ-mediated insertions or deletions.
Applications include:
- Functional genomics
- Drug target validation
- Disease mechanism studies
Gene Knock-In
Precise insertion of defined DNA sequences using HDR.
Examples include:
- GFP reporters
- Epitope tags
- Disease-associated mutations
Point Mutation Engineering
Single nucleotide variants can be introduced or corrected to generate clinically relevant disease models.
Typical applications include:
- Variant interpretation
- Precision disease modeling
- Mutation correction
Reporter Cell Lines
Reporter lines enable visualization and purification of specific cell populations during differentiation.
Common reporters include:
| Cell Type | Representative Reporters |
|---|---|
| Neurons | MAP2-GFP, SYN1-GFP, TH-GFP |
| Astrocytes | GFAP-GFP |
| Oligodendrocytes | MBP-GFP |
| Microglia | TMEM119-GFP |
Applications include:
- Live-cell imaging
- Cell sorting
- Differentiation tracking
Isogenic Controls
One of the most important applications of genome editing.
Two complementary strategies are commonly used:
Disease Model Generation
Healthy iPSC → Introduce mutation → Disease model
Mutation Correction
Patient iPSC → Correct mutation → Isogenic control
Isogenic pairs minimize variability arising from differences in genetic background and improve interpretation of experimental results.
Disease Modeling Applications
Genome editing has become central to modeling numerous human disorders.
Common examples include:
| Disease | Frequently Edited Genes |
|---|---|
| Alzheimer's disease | APP, PSEN1, PSEN2, APOE, TREM2 |
| Parkinson's disease | LRRK2, SNCA, PARK2, GBA1 |
| ALS | SOD1, C9orf72, TARDBP, FUS |
| Huntington's disease | HTT |
Quality Control After Editing
Edited iPSC lines should undergo complete re-characterization before downstream experiments.
Typical quality control includes:
- Mutation confirmation by sequencing
- Karyotype analysis
- Pluripotency marker assessment
- Mycoplasma testing
- Differentiation capacity verification
Advantages
- Precise genome modification
- Human disease modeling
- Generation of isogenic controls
- Compatible with patient-derived iPSCs
- Broad applicability across research fields
Limitations
- Off-target editing
- Variable editing efficiency
- HDR is often inefficient
- Clone-to-clone variability
- Extensive validation required
Emerging Technologies
New genome engineering approaches continue to expand the capabilities of iPSC research, including:
- Prime editing
- Epigenome editing
- RNA editing
- Multiplex CRISPR systems
- CRISPR-associated transposases
These technologies are expected to further improve precision disease modeling and regenerative medicine.
Key Takeaways
- Genome editing enables precise genetic manipulation of human iPSCs.
- CRISPR-Cas9 remains the most widely used editing platform, while base and prime editing provide increasingly precise alternatives.
- Isogenic controls generated by mutation introduction or correction represent the gold standard for mechanistic disease studies.
- All edited iPSC lines require comprehensive quality control before experimental use.
References
- Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science (2014).
- Hsu PD et al. Development and applications of CRISPR-Cas9. Cell (2014).
- Komor AC et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature (2016).
- Anzalone AV et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature (2019).